New Bavarian Biotech Report

09. July 2024

With its annual report "Biotech in Bavaria 23/24", the BioM cluster organization presents a picture of the industry - including biotechnology in the Munich region.

Economic environment and trends

With its Biotech in Bavaria 2023/24 - Incubating Science for Health report, the Bio^M cluster organization once again presents an up-to-date picture of the industry. In addition to current figures for Bavaria, the brochure is dedicated to the start-up landscape, the drug pipeline, portraits of influential organizations and players, plus relevant international market data and forward-looking research approaches and financing.

Photo: BioM

Developments in Bavaria and Munich

The Bavarian biopharmaceutical industry is once again showing impressive growth and stability despite global economic challenges.

The number of employees grew by 7,000 to 58,000 (+14%), once again reaching an all-time high, with biotechnology companies making the main contribution.

Overall, the industry in Bavaria can look back on record investments and significant financing rounds in 2023/24: The investment round of €255 million for the radiopharmaceutical company ITM in Garching was outstanding. Amsilk, Ethris, mbiomics, deepc, Bind-X and Formycon, all based in Munich or the district, also reported successful financing rounds.

Among the large companies, Roche is investing 90 million euros in a new gene therapy development center in Penzberg and a further 600 million euros in a diagnostics research building there. Daiichi Sankyo is planning around EUR 1 billion for an international innovation center in Pfaffenhofen, north of Munich, and Sandoz is also investing EUR 25 million in a biosimilar development center in Holzkirchen, southeast of Munich. Minaris is expanding its production for cell and gene therapeutics in Taufkirchen and ITM has built a new production site for the radioisotope Lutetium-177 in Neufahrn near Freising.

Drug development continued to be dominated by oncology, followed by autoimmune diseases.

Biotech in Bavaria 2023/24 (epaper)

Munich region start-ups

The report once again confirms that the Munich region has a start-up-friendly ecosystem. The city and district of Munich are home to 9 of the new companies out of a total of 11 newly founded and two newly established companies in Bavaria.

In Bavaria, 71 percent of companies currently rate the current business situation as good or very good; this is nine percent more than in the previous year.

The presentation of the Bio^MReport Biotech in Bavaria 2023/24 - Incubating Science for Health took place on July 3, 2024 as part of Bio^M's new biotechnology conference "BayOConnect - Forum for Biotech & LifeScience 2024".

Biotech in Bavaria 2023/24 - Tabelle Startups und neue Unternehmen (S.8) © BioM

Photo: BioM

List of new companies in Bavaria 2023/24

About the Biotech in Bavaria report

As a network organization for the biotechnology sector in Munich and Bavaria, Bio^M produces the annual Biotech in Bavaria report on the development of the Bavarian biotechnology and pharmaceutical sector on behalf of the Bavarian Ministry of Economic Affairs. This report records current industry figures, trends and selected examples of the innovative strength of science and entrepreneurship in Bavaria.